Degron Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$40M
- Investors
-
19
Degron Therapeutics General Information
Description
Developer of molecular glue-based small-molecule drugs intended for therapeutic development for complex diseases. The company offers innovative protein degradation drugs; it uses molecular glial protein degradation platform technology to discover new drugs, enabling clients to improve treatment efficiency.
Contact Information
Website
www.degrontx.comCorporate Office
- 3rd Floor, Building 3, Yuesong Life Science Park
- Number 998, Halei Road, Pudong New Area
- Shanghai, 201203
- China
Corporate Office
- 3rd Floor, Building 3, Yuesong Life Science Park
- Number 998, Halei Road, Pudong New Area
- Shanghai, 201203
- China
Degron Therapeutics Timeline
Degron Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A2) | 15-May-2026 | $40M | Completed | Generating Revenue | ||
| 5. Later Stage VC | 29-Dec-2025 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A1) | 22-Jan-2025 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-May-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 09-Jun-2022 | $22M | $23.5M | Completed | Generating Revenue | |
| 1. Early Stage VC | 01-Apr-2021 | $1.53M | $1.53M | Completed | Generating Revenue |
Degron Therapeutics Comparisons
Industry
Financing
Details
Degron Therapeutics Competitors (2)
One of Degron Therapeutics’s 2 competitors is JW Therapeutics, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| JW Therapeutics | Formerly VC-backed | Shanghai, China | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China |
Degron Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Degron Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Degron Therapeutics Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Fortune Capital | Venture Capital | Minority | ||
| GF Xinde Investment Management | PE/Buyout | Minority | ||
| Guotai Junan securities (Hong Kong) | Investment Bank | Minority | ||
| Jinhe Capital | Growth/Expansion | Minority | ||
| Lapam Capital | Venture Capital | Minority |
Degron Therapeutics FAQs
-
When was Degron Therapeutics founded?
Degron Therapeutics was founded in 2019.
-
Where is Degron Therapeutics headquartered?
Degron Therapeutics is headquartered in Shanghai, China.
-
What is the size of Degron Therapeutics?
Degron Therapeutics has 35 total employees.
-
What industry is Degron Therapeutics in?
Degron Therapeutics’s primary industry is Drug Discovery.
-
Is Degron Therapeutics a private or public company?
Degron Therapeutics is a Private company.
-
What is Degron Therapeutics’s current revenue?
The current revenue for Degron Therapeutics is .
-
How much funding has Degron Therapeutics raised over time?
Degron Therapeutics has raised $83.5M.
-
Who are Degron Therapeutics’s investors?
Fortune Capital, GF Xinde Investment Management, Guotai Junan securities (Hong Kong), Jinhe Capital, and Lapam Capital are 5 of 19 investors who have invested in Degron Therapeutics.
-
Who are Degron Therapeutics’s competitors?
JW Therapeutics and BeOne Medicines are competitors of Degron Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
